HYPDNasdaqFinance ServicesUS GAAP · USD

Hyperion DeFi, Inc

Hyperion DeFi, Inc. is a U.S.-listed company that has pivoted from its former Eyenovia ophthalmic technology business into a digital-asset treasury and on-chain revenue model centered on the Hyperliquid ecosystem. It holds HYPE tokens, operates validator-related services, and has launched products such as HAUS to monetize access to staked HYPE, while still pursuing development of its Optejet ophthalmic liquid delivery device.

Liikevaihto0,8milj. USD
+1 318,8 %v/v
Liikevoitto (EBIT)−46,7milj. USD
+4,1 %v/v
EBIT-marginaali−5 743,5%
+79 261,0 %-yks.v/v
Nettotulos−45,3milj. USD
+9,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−60−40−20020milj. USD2020: 2,0 milj. USD2020: EBIT −20 milj. USD20202021: 14 milj. USD2021: EBIT −13 milj. USD20212022: 14 milj. USD2022: EBIT −27 milj. USD20222023: 0,00 milj. USD2023: EBIT −25 milj. USD20232024: 0,06 milj. USD2024: EBIT −49 milj. USD20242025: 0,81 milj. USD2025: EBIT −47 milj. USD20250,81−47
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Digital asset treasury0 %

Acquisition and holding of HYPE tokens as the core balance-sheet strategy.

Validator and staking services55 %

Network validation, staking rewards, and commission income earned on Hyperliquid.

HYPE Asset Use Service (HAUS)25 %

On-chain service that lends staked HYPE access in exchange for fee savings sharing.

HIP-3 market support15 %

Providing HYPE to enable custom perpetual futures markets and earn fee shares.

Ophthalmic device development5 %

Legacy Optejet development and registration work for liquid ophthalmic delivery.

Asiakkaat

The company’s direct customers are mainly trading firms, market participants, and protocol users that want exposure to Hyperliquid network benefits without holding HYPE directly. It also effectively serves the Hyperliquid ecosystem itself by providing validator support and liquidity-related services that help drive trading activity and fee generation. On the legacy side, any eventual Optejet commercialization would target ophthalmology and eye-care channels, but that remains a development-stage activity.

Proprietary trading firms

They use HAUS and related HYPE access arrangements to reduce trading fees and share savings.

Hyperliquid network participants

Users and delegators rely on validator operations and staking-related services for network participation.

DeFi and crypto traders

They generate activity on Hyperliquid that supports fee pools and ecosystem monetization.

Protocol builders and deployers

They may use HYPE-supported HIP-3 deployments to launch custom perpetual markets.

Ophthalmology end markets

Potential future buyers of Optejet if the device is completed and registered.

Strategia

The company’s current strategy is to build a long-term HYPE treasury and monetize Hyperliquid network utility through staking, validator operations, and fee-sharing products. Management describes this as a broader DeFi monetization roadmap, while still preserving optionality in its ophthalmic technology program. The strategy depends on Hyperliquid adoption, network economics, and the company’s ability to create products that convert token utility into recurring revenue.

Build and defend the HYPE treasuryLyhyt aikaväli

Treasury value and market perception are tied to HYPE accumulation and holding discipline.

Scale on-chain monetizationKeskipitkä aikaväli

Recurring fee-sharing and validator income can diversify revenue beyond token appreciation.

Expand ecosystem utilityKeskipitkä aikaväli

Greater Hyperliquid adoption increases demand for HYPE and related services.

Maintain legacy device optionalityPitkä aikaväli

Optejet could provide a non-crypto operating path if development and registration progress.

Maantiede

Hyperion DeFi is headquartered in Laguna Hills, California and is organized in the United States, so its corporate, regulatory, and capital-markets exposure is primarily U.S.-based. Its operating model is economically tied to the global Hyperliquid network, which means demand, liquidity, and regulatory risk are driven by international digital-asset markets rather than a single country. The company’s legacy device business would also depend on U.S. and potentially international medical-device commercialization pathways.

Riskit

The company is highly exposed to HYPE price volatility, liquidity constraints, and the continued adoption of the Hyperliquid protocol, so its financial results can swing sharply with token markets. It also faces regulatory, custody, and network-centralization risks that are common in digital assets, plus execution risk in turning experimental on-chain products into durable revenue. The legacy ophthalmic device program adds development and commercialization uncertainty, but the dominant risk driver is the concentration in a single crypto ecosystem.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →HYPE token price volatility1Liquidity constraints in digital assets2Regulatory and enforcement actions3Validator centralization and network failure4Protocol competition and technological obsolescence5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. HYPE token price volatilityVaikutus: KriittinenTodennäköisyys: Korkea

    Treasury assets and market valuation are heavily tied to HYPE, which can move sharply.

    Kohdistuu: Substantially all treasury assets are concentrated in HYPE tokens.

  2. Liquidity constraints in digital assetsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    HYPE cannot be converted to cash as readily as traditional treasury assets.

    Kohdistuu: Treasury management and working capital flexibility.

  3. Regulatory and enforcement actionsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    New rules or enforcement could limit access to HYPE, trading venues, or custody providers.

    Kohdistuu: U.S. and foreign digital asset regulation.

  4. Validator centralization and network failureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    A limited validator set can create single points of failure or governance risk.

    Kohdistuu: Hyperliquid network integrity and HYPE value.

  5. Protocol competition and technological obsolescenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Alternative blockchains and AI-enabled protocols may attract users and developers away.

    Kohdistuu: Hyperliquid ecosystem adoption and fee generation.

Kirjanpito

Harkinnanvaraiset erät
Digital intangible asset impairment

HYPE is carried at cost net of impairments, so market declines can trigger charges.

Vaikutus: Can materially reduce operating income without affecting cash flow.

Fair value measurement of noncash HYPE revenue

Validator rewards and commission income are measured at fair value when earned.

Vaikutus: Affects reported revenue and period-to-period comparability.

Revenue recognition for validator services

Revenue is recognized as performance obligations are satisfied over the epoch.

Vaikutus: Timing of block validation can shift quarterly revenue.

Critical estimates and assumptions

Management must estimate fair values and impairment thresholds under U.S. GAAP.

Vaikutus: Small assumption changes can materially affect reported results.

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026